Maria Ida Maiorino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9412117/publications.pdf

Version: 2024-02-01

57758 74163 6,767 173 44 citations h-index papers

g-index 177 177 177 9108 docs citations times ranked citing authors all docs

75

#	Article	IF	CITATIONS
1	Thyroid surgery during the COVID-19 pandemic: results from a systematic review. Journal of Endocrinological Investigation, 2022, 45, 181-188.	3.3	11
2	Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring. Journal of Endocrinological Investigation, 2022, 45, 445-452.	3.3	9
3	Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues. Biomolecules, 2022, 12, 272.	4.0	11
4	The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovascular Diabetology, 2022, 21, 42.	6.8	54
5	Change in Circulating Levels of Endothelial Progenitor Cells and Sexual Function in Women With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, , .	3.6	1
6	Applications for social security benefits related to diabetes in the working age in Italy between 2009 and 2019: a nationwide retrospective cohort study. BMJ Open, 2022, 12, e057825.	1.9	0
7	European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events. Pharmaceuticals, 2022, 15, 677.	3.8	8
8	Graves' hyperthyroidism-related pancytopenia: a case report with literature review. Hormones, 2021, 20, 93-100.	1.9	7
9	Female Sexual Function in Young Women With Type 1 Diabetes and Additional Autoimmune Diseases. Journal of Sexual Medicine, 2021, 18, 219-223.	0.6	4
10	Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis. Thyroid, 2021, 31, 884-894.	4.5	25
11	Neutropenia in patients with hyperthyroidism: Systematic review and metaâ€analysis. Clinical Endocrinology, 2021, 94, 473-483.	2.4	21
12	New insights into vitamin D regulation: is there a role for alkaline phosphatase?. Journal of Endocrinological Investigation, 2021, 44, 1891-1896.	3.3	8
13	The residual cardiorenal risk in type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 36.	6.8	14
14	<scp>S</scp> odiumâ€glucose coâ€transporterâ€2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 1672-1676.	4.4	30
15	Teleassistance for Patients With Type 1 Diabetes During the COVID-19 Pandemic: Results of a Pilot Study. Journal of Medical Internet Research, 2021, 23, e24552.	4.3	17
16	Obesity in Prader–Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches. Journal of Endocrinological Investigation, 2021, 44, 2057-2070.	3.3	43
17	Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Diabetes Care, 2021, 44, 1353-1360.	8.6	22
18	Sexual dysfunctions and short-term glucose variability in young men with type 1 diabetes. Hormones, 2021, 20, 475-482.	1.9	4

#	Article	IF	CITATIONS
19	Antibiotic resistance in diabetic foot infection: how it changed with COVID-19 pandemic in a tertiary care center. Diabetes Research and Clinical Practice, 2021, 175, 108797.	2.8	18
20	Chronothyroidology: Chronobiological Aspects in Thyroid Function and Diseases. Life, 2021, 11, 426.	2.4	5
21	Up and down waves of glycemic control and lower-extremity amputation in diabetes. Cardiovascular Diabetology, 2021, 20, 135.	6.8	7
22	Hypothalamic-Pituitary Autoimmunity and Related Impairment of Hormone Secretions in Chronic Fatigue Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5147-e5155.	3.6	8
23	Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. Cancers, 2021, 13, 4036.	3.7	3
24	Simplification of complex insulin therapy: a story of dogma and therapeutic resignation. Diabetes Research and Clinical Practice, 2021, 178, 108958.	2.8	9
25	Renal and metabolic effects of SGLT-2i and DPP-4i according to basal estimated glomerular filtration rate: Analysis from GIOIA, an observational prospective study. Diabetes Research and Clinical Practice, 2021, 178, 108990.	2.8	0
26	GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovascular Diabetology, 2021, 20, 189.	6.8	104
27	Mediterranean diet in type 2 diabetes: An updated overview of pharmacological activities of cardiometabolic and reproductive outcomes. Current Opinion in Pharmacology, 2021, 60, 27-33.	3.5	6
28	Effects of Mediterranean diet on semen parameters in healthy young adults: a randomized controlled trial. Minerva Endocrinologica, 2021, 45, 280-287.	1.8	8
29	Reply to the letter to the editor by Mungmunpuntipantip et al Journal of Endocrinological Investigation, 2021, , 1.	3.3	2
30	Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovascular Diabetology, 2021, 20, 210.	6.8	31
31	Exploring the Performance of Ultrasound Risk Stratification Systems in Thyroid Nodules of Pediatric Patients. Cancers, 2021, 13, 5304.	3.7	24
32	SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovascular Diabetology, 2021, 20, 236.	6.8	63
33	Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis. Stroke, 2020, 51, 666-669.	2.0	42
34	Mediterranean Diet and COVID-19: Hypothesizing Potential Benefits in People With Diabetes. Frontiers in Endocrinology, 2020, 11, 574315.	3.5	28
35	Diabetic Foot Problems During the COVID-19 Pandemic in a Tertiary Care Center: The Emergency Among the Emergencies. Diabetes Care, 2020, 43, e123-e124.	8.6	60
36	Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies. Cardiovascular Diabetology, 2020, 19, 115.	6.8	33

3

#	Article	IF	CITATIONS
37	Comment on MÃkimattila et al. Every Fifth Individual With Type 1 Diabetes Suffers From an Additional Autoimmune Disease: A Finnish Nationwide Study. Diabetes Care 2020;43:1041–1047. Diabetes Care, 2020, 43, e105-e105.	8.6	1
38	Glycemic control in people with type 1 diabetes using a hybrid closed loop system and followed by telemedicine during the COVID-19 pandemic in Italy. Diabetes Research and Clinical Practice, 2020, 169, 108440.	2.8	34
39	Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2020, 43, 1146-1156.	8.6	155
40	Endocrine complications of COVID-19: what happens to the thyroid and adrenal glands?. Journal of Endocrinological Investigation, 2020, 43, 1169-1170.	3.3	45
41	Glucose monitoring in diabetes: A suggested algorithm to choice the best treatment option. Diabetes Research and Clinical Practice, 2020, 165, 108242.	2.8	3
42	Sexual dysfunctions in young women with type 1 diabetes and high glucose variability: findings from the METRO study. Journal of Endocrinological Investigation, 2020, 43, 1823-1825.	3.3	3
43	Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Research and Clinical Practice, 2020, 162, 108114.	2.8	29
44	Antibodies Against Hypothalamus and Pituitary Gland in Childhood-Onset Brain Tumors and Pituitary Dysfunction. Frontiers in Endocrinology, 2020, 11, 16.	3.5	9
45	Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney. Cardiovascular Diabetology, 2020, 19, 35.	6.8	24
46	<p>Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 777-784.	2.4	4
47	Impact of Pituitary Autoimmunity and Genetic Disorders on Growth Hormone Deficiency in Children and Adults. International Journal of Molecular Sciences, 2020, 21, 1392.	4.1	5
48	Different Formulations of Levothyroxine for Treating Hypothyroidism: A Real-Life Study. International Journal of Endocrinology, 2020, 2020, 1-5.	1.5	17
49	Long-term diabetic complications as predictors of foot ulcers healing failure: A retrospective study in a tertiary-care center. Diabetes Research and Clinical Practice, 2020, 163, 108147.	2.8	13
50	Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A metaâ€analysis with metaâ€regression. Diabetes, Obesity and Metabolism, 2020, 22, 1397-1405.	4.4	27
51	Diabetes and Sexual Disorders. Endocrinology, 2020, , 473-494.	0.1	2
52	Diabetes and Sexual Disorders. Endocrinology, 2020, , 1-22.	0.1	1
53	Type 1 diabetes triggered by covid-19 pandemic: A potential outbreak?. Diabetes Research and Clinical Practice, 2020, 164, 108219.	2.8	45
54	Remission of Pituitary Autoimmunity Induced by Gluten-Free Diet in Patients With Celiac Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2252-2261.	3.6	7

#	Article	IF	CITATIONS
55	GLPâ€1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated metaâ€analysis including the REWIND and PIONEER 6 trials. Diabetes, Obesity and Metabolism, 2019, 21, 2576-2580.	4.4	104
56	Metabolic effectiveness of gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre study. Diabetes Research and Clinical Practice, 2019, 155, 107787.	2.8	3
57	Beyond basal-bolus insulin regimen: Is it still the ultimate chance for therapy in diabetes?. Diabetes Research and Clinical Practice, 2019, 157, 107922.	2.8	5
58	Measuring the Quality of Diabetes Care. JAMA - Journal of the American Medical Association, 2019, 322, 1212.	7.4	1
59	The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 154, 101-115.	2.8	19
60	Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Metaâ€Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. Journal of the American Heart Association, 2019, 8, e012356.	3.7	73
61	Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials. Endocrine, 2019, 65, 15-24.	2.3	25
62	The role of autoimmunity in pituitary dysfunction due to traumatic brain injury. Pituitary, 2019, 22, 236-248.	2.9	14
63	Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis. Journal of Endocrinological Investigation, 2019, 42, 1165-1169.	3.3	28
64	EMPATHY: A New Tool for Identifying the Most Suitable Thyroxine Formulation in Hypothyroid Patients. Thyroid, 2019, 29, 928-933.	4.5	10
65	Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2019, 21, 1790-1800.	4.4	28
66	Endocrine rhythms and sport: it is time to take time into account. Journal of Endocrinological Investigation, 2019, 42, 1137-1147.	3.3	13
67	Are gliflozins the new statins for diabetes?. Diabetes Research and Clinical Practice, 2019, 153, 191-193.	2.8	5
68	Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. Frontiers in Endocrinology, 2019, 10, 45.	3.5	94
69	Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. Journal of Endocrinological Investigation, 2019, 42, 495-503.	3.3	48
70	Dissonance among treatment algorithms for hyperglycemia in type 2 diabetes: an egalitarian dialog. Journal of Endocrinological Investigation, 2019, 42, 237-242.	3.3	2
71	Diabetes and Sexual Disorders. Endocrinology, 2019, , 1-22.	0.1	0
72	Gender-differences in glycemic control and diabetes related factors in young adults with type 1 diabetes: results from the METRO study. Endocrine, 2018, 61, 240-247.	2.3	19

#	Article	IF	Citations
73	Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care 2017;40:1425–1432. Diabetes Care, 2018, 41, e17-e17.	8.6	5
74	Comment on "The pros and cons of continuous glucose monitoring for patients with type 1 diabetes on multiple daily injections of insulin― Authors' reply. Endocrine, 2018, 60, 197-197.	2.3	0
75	Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine, 2018, 61, 23-27.	2.3	36
76	The Effects of Subcutaneous Insulin Infusion Versus Multiple Insulin Injections on Glucose Variability in Young Adults with Type 1 Diabetes: The 2-Year Follow-Up of the Observational METRO Study. Diabetes Technology and Therapeutics, 2018, 20, 117-126.	4.4	24
77	From inflammation to sexual dysfunctions: a journey through diabetes, obesity, and metabolic syndrome. Journal of Endocrinological Investigation, 2018, 41, 1249-1258.	3.3	101
78	More sugar? No, thank you! The elusive nature of low carbohydrate diets. Endocrine, 2018, 61, 383-387.	2.3	22
79	Continuous glucose monitoring for patients with type 1 diabetes on multiple daily injections of insulin: pros and cons. Endocrine, 2018, 59, 62-65.	2.3	9
80	TSH oscillations in young patients with type 1 diabetes may be due to glycemic variability. Journal of Endocrinological Investigation, 2018, 41, 389-393.	3.3	9
81	Type 2 diabetes and cardiovascular prevention: the dogmas disputed. Endocrine, 2018, 60, 224-228.	2.3	11
82	Diabetes is a cardiovascular disease, isn't it?. Diabetes Research and Clinical Practice, 2018, 135, 229-231.	2.8	6
83	An Italian Survey of Compliance With Major Guidelines for L-Thyroxine of Primary Hypothyroidism. Endocrine Practice, 2018, 24, 419-428.	2.1	13
84	Metabolic syndrome and cancer: "The common soil hypothesis― Diabetes Research and Clinical Practice, 2018, 143, 389-397.	2.8	70
85	Diabetes and Sexual Disorders. Endocrinology, 2018, , 1-22.	0.1	1
86	Free and fixedâ€ratio combinations of basal insulin and GLPâ€1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 2309-2313.	4.4	32
87	Particulate matter air pollution: individual choices for improving cardiometabolic well-being. Endocrine, 2018, 59, 495-498.	2.3	3
88	Diabetes and Sexual Disorders. Endocrinology, 2018, , 473-494.	0.1	0
89	Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?. Endocrine, 2017, 55, 360-365.	2.3	27
90	Premixed insulin regimens in type 2 diabetes: pros. Endocrine, 2017, 55, 45-50.	2.3	7

#	Article	IF	CITATIONS
91	Mediterranean diet for type 2 diabetes: cardiometabolic benefits. Endocrine, 2017, 56, 27-32.	2.3	88
92	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. Nutrition Reviews, 2017, 75, 307-326.	5.8	294
93	Sexual dysfunctions in diabetes: a gender issue. Journal of Diabetes and Its Complications, 2017, 31, 785-786.	2.3	4
94	Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2017, 40, 614-624.	8.6	97
95	Insights into the relationships between diabetes, prediabetes, and cancer. Endocrine, 2017, 56, 231-239.	2.3	63
96	Natural history of autoimmune primary ovarian insufficiency in patients with Addison's disease: from normal ovarian function to overt ovarian dysfunction. European Journal of Endocrinology, 2017, 177, 329-337.	3.7	8
97	Effect of a Mediterranean diet on endothelial progenitor cells and carotid intima-media thickness in type 2 diabetes: Follow-up of a randomized trial. European Journal of Preventive Cardiology, 2017, 24, 399-408.	1.8	59
98	Can diet prevent diabetes?. Journal of Diabetes and Its Complications, 2017, 31, 288-290.	2.3	10
99	Sexual function in young women with type 1 diabetes: the METRO study. Journal of Endocrinological Investigation, $2017, 40, 169-177$.	3.3	36
100	Erectile dysfunction in young men with type 1 diabetes. International Journal of Impotence Research, 2017, 29, 17-22.	1.8	30
101	Intensive Lifestyle Intervention for Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 2494.	7.4	1
102	Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In <i>Standards of Medical Care in Diabetes—2016</i> . Diabetes Care 2016;39(Suppl. 1):S52–S59. Diabetes Care, 2016, 39, e86-e87.	8.6	16
103	Mediterranean diet cools down the inflammatory milieu in type 2 diabetes: the MÉDITA randomized controlled trial. Endocrine, 2016, 54, 634-641.	2.3	43
104	Effects of Mediterranean diet on sexual function in people with newly diagnosed type 2 diabetes: The MÃ^DITA trial. Journal of Diabetes and Its Complications, 2016, 30, 1519-1524.	2.3	60
105	Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. Pituitary, 2016, 19, 625-642.	2.9	94
106	Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert Opinion on Drug Safety, 2016, 15, 77-83.	2.4	27
107	Comment on Mita et al. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Diabetes Care 2016;39:455–464. Diabetes Care. 2016. 39. e102-e103.	8.6	3
108	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. Endocrine, 2016, 54, 32-37.	2.3	1

#	Article	IF	Citations
109	Primary Prevention of Sexual Dysfunction With Mediterranean Diet in Type 2 Diabetes: The MÃ^DITA Randomized Trial. Diabetes Care, 2016, 39, e143-e144.	8.6	22
110	Particulate matter pollutants and risk of type 2 diabetes: a time for concern?. Endocrine, 2016, 51, 32-37.	2.3	54
111	Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index. Endocrine, 2016, 54, 329-341.	2.3	84
112	Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes. Endocrine, 2016, 53, 220-226.	2.3	19
113	Anti-inflammatory Effect of Mediterranean Diet in Type 2 Diabetes Is Durable: 8-Year Follow-up of a Controlled Trial. Diabetes Care, 2016, 39, e44-e45.	8.6	23
114	Longitudinal behavior of autoimmune GH deficiency: from childhood to transition age. European Journal of Endocrinology, 2016, 174, 381-387.	3.7	15
115	Mass Treatment With Bariatric Surgery for Type 2 Diabetes Mellitus. JAMA Surgery, 2016, 151, 196.	4.3	0
116	Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine, 2016, 51, 417-428.	2.3	68
117	Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study. Endocrine, 2016, 52, 244-252.	2.3	30
118	Comment on Krul-Poel et al. Effect of Vitamin D Supplementation on Glycemic Control in Patients With Type 2 Diabetes (SUNNY Trial): A Randomized Placebo-Controlled Trial. Diabetes Care 2015;38:1420–1426. Diabetes Care, 2015, 38, e168-e168.	8.6	0
119	Lifestyle modifications and erectile dysfunction: what can be expected?. Asian Journal of Andrology, 2015, 17, 5.	1.6	89
120	A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open, 2015, 5, e008222.	1.9	368
121	Vitamin D and autoimmunity: what happens in autoimmune polyendocrine syndromes?. Journal of Endocrinological Investigation, 2015, 38, 629-633.	3.3	24
122	Circulating endothelial progenitor cells in type 1 diabetic patients with erectile dysfunction. Endocrine, 2015, 49, 415-421.	2.3	21
123	Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither?. Endocrine, 2015, 50, 56-60.	2.3	6
124	A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open, 2015, 5, e005892-e005892.	1.9	63
125	Linking prediabetes and cancer: a complex issue. Diabetologia, 2015, 58, 201-202.	6.3	4
126	Premature Ejaculation is Associated with Glycemic Control in Type 1 Diabetes. Journal of Sexual Medicine, 2015, 12, 93-99.	0.6	18

#	Article	IF	Citations
127	Glucose variability inversely associates with endothelial progenitor cells in type 1 diabetes. Endocrine, 2015, 48, 342-345.	2.3	14
128	Remission of type 2 diabetes: is bariatric surgery ready for prime time?. Endocrine, 2015, 48, 417-421.	2.3	23
129	Comment on Tay et al. A Very Low-Carbohydrate, Low–Saturated Fat Diet for Type 2 Diabetes Management: A Randomized Trial. Diabetes Care 2014;37:2909–2918. Diabetes Care, 2015, 38, e64-e64.	8.6	2
130	Diabetes and sexual dysfunction: current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 95.	2.4	157
131	Comment on Grunberger "Insulin Analogs—Are They Worth It? Yes!―Diabetes Care 2014;37:1767–1770 Davidson "Insulin Analogs—Is There a Compelling Case to Use Them? No!―Diabetes Care 2014;37:1771–1774. Diabetes Care, 2014, 37, e229-e230.	and 8.6	3
132	Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417. Diabetes Care, 2014, 37, e113-e113.	8.6	2
133	Comment on Home et al. Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. Diabetes Care 2014;37:1237–1245. Diabetes Care, 2014, 37, e183-e183.	8.6	2
134	Vitamin D Deficiency in Type 2 Diabetic Patients with Hypogonadism. Journal of Sexual Medicine, 2014, 11, 536-542.	0.6	24
135	Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open, 2014, 4, e005442-e005442.	1.9	56
136	Sexual Activity in Midlife Women and Beyond. JAMA Internal Medicine, 2014, 174, 1203.	5.1	2
137	Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine, 2014, 45, 28-36.	2.3	123
138	Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors. Endocrine, 2014, 46, 43-51.	2.3	44
139	New guidelines for metabolic targets in diabetes: clinician's opinion does matter. Endocrine, 2014, 46, 431-434.	2.3	5
140	The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?. Expert Opinion on Biological Therapy, 2014, 14, 799-808.	3.1	19
141	Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI. Endocrine, 2014, 46, 256-262.	2.3	32
142	Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies. Endocrine, 2014, 47, 107-116.	2.3	112
143	The Effects of a Mediterranean Diet on the Need for Diabetes Drugs and Remission of Newly Diagnosed Type 2 Diabetes: Follow-up of a Randomized Trial. Diabetes Care, 2014, 37, 1824-1830.	8.6	149
144	Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine, 2013, 44, 634-647.	2.3	152

#	Article	IF	CITATIONS
145	Effect of metabolic syndrome and its components on prostate cancer risk: Meta-analysis. Journal of Endocrinological Investigation, 2013, 36, 132-139.	3.3	112
146	Anti-Pituitary Antibodies and Hypogonadotropic Hypogonadism in Type 2 Diabetes: In Search of a Role. Diabetes Care, 2013, 36, e116-e117.	8.6	13
147	Comment on: Wing et al. Effect of Intensive Lifestyle Intervention on Sexual Dysfunction in Women With Type 2 Diabetes: Results From an Ancillary Look AHEAD Study. Diabetes Care 2013;36:2937–2944. Diabetes Care, 2013, 36, e190-e190.	8.6	1
148	Metabolic syndrome and postmenopausal breast cancer. Menopause, 2013, 20, 1301-1309.	2.0	110
149	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy & Design, Development and Therapy, 2013, 7, 989.	4.3	41
150	Female sexual dysfunction in women with thyroid disorders. Journal of Endocrinological Investigation, 2013, 36, 729-33.	3.3	20
151	Circulating endothelial progenitor cells in acromegaly. Journal of Endocrinological Investigation, 2013, 36, 825-30.	3.3	4
152	Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes, Obesity and Metabolism, 2012, 14, 228-233.	4.4	119
153	Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review. Diabetes Research and Clinical Practice, 2011, 92, 1-10.	2.8	50
154	Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes-a randomized controlled trial. Diabetes, Obesity and Metabolism, 2011, 13, 439-445.	4.4	63
155	Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2011, 13, 594-603.	4.4	92
156	Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review. Journal of Diabetes and Its Complications, 2011, 25, 275-281.	2.3	17
157	Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of & Diabetes in Type 2 Diabetes. Diabetes Care, 2011, 34, 510-517.	8.6	116
158	Long-Term Effect of Mediterranean-Style Diet and Calorie Restriction on Biomarkers of Longevity and Oxidative Stress in Overweight Men. Cardiology Research and Practice, 2011, 2011, 1-5.	1.1	37
159	Insulin Analogs and Glycosylated Hemoglobin Target of Less Than 7% in Type 2 Diabetes: A Systematic Review of Randomized Trials. Metabolic Syndrome and Related Disorders, 2011, 9, 167-176.	1.3	2
160	ORIGINAL RESEARCHâ€"ERECTILE DYSFUNCTION: Adherence to Mediterranean Diet and Erectile Dysfunction in Men with Type 2 Diabetes. Journal of Sexual Medicine, 2010, 7, 1911-1917.	0.6	49
161	ORIGINAL RESEARCH—WOMEN'S SEXUAL HEALTH: Adherence to Mediterranean Diet and Sexual Function in Women with Type 2 Diabetes. Journal of Sexual Medicine, 2010, 7, 1883-1890.	0.6	44
162	Dietary Factors, Mediterranean Diet and Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 2338-2345.	0.6	58

#	Article	lF	CITATIONS
163	Determinants of female sexual dysfunction in type 2 diabetes. International Journal of Impotence Research, 2010, 22, 179-184.	1.8	144
164	Dietary Glycemic Index and Glycemic Load Are Associated with Metabolic Control in Type 2 Diabetes: The CAPRI Experience. Metabolic Syndrome and Related Disorders, 2010, 8, 255-261.	1.3	14
165	Prevention and control of type 2 diabetes by Mediterranean diet: A systematic review. Diabetes Research and Clinical Practice, 2010, 89, 97-102.	2.8	170
166	Interleukin-20 circulating levels in obese women: Effect of weight loss. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 180-185.	2.6	18
167	Circulating CD34+KDR+ Endothelial Progenitor Cells Correlate with Erectile Function and Endothelial Function in Overweight Men. Journal of Sexual Medicine, 2009, 6, 107-114.	0.6	60
168	Hyperlipidemia and Sexual Function in Premenopausal Women. Journal of Sexual Medicine, 2009, 6, 1696-1703.	0.6	45
169	Adherence to a Mediterranean diet and glycaemic control in Type 2 diabetes mellitus. Diabetic Medicine, 2009, 26, 900-907.	2.3	84
170	Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in Patients With Newly Diagnosed Type 2 Diabetes. Annals of Internal Medicine, 2009, 151, 306.	3.9	380
171	Lifestyle approach for type 2 diabetes and metabolic syndrome. Current Atherosclerosis Reports, 2008, 10, 523-528.	4.8	20
172	Phenotypic Assessment of Endothelial Microparticles in Diabetic and Nondiabetic Men with Erectile Dysfunction. Journal of Sexual Medicine, 2008, 5, 1436-1442.	0.6	41
173	Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control. Annals of Internal Medicine, 2008, 149, 531.	3.9	49